4.5 Article

Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Journal

EUROINTERVENTION
Volume 18, Issue 15, Pages 1227-+

Publisher

EUROPA EDITION
DOI: 10.4244/EIJ-D-22-00723

Keywords

hypertension; renal sympathetic denervation; resistant hypertension; uncontrolled hypertension

Ask authors/readers for more resources

According to the 2018 ESC/ESH guidelines, radiofrequency and ultrasound renal denervation (RDN) have been proven effective and safe in lowering blood pressure in a broad range of patients with hypertension, including resistant hypertension. The expert group suggests that RDN can be used as an adjunct treatment option in uncontrolled resistant hypertension, especially in patients with high cardiovascular risk or hypertension-mediated organ damage. Multidisciplinary hypertension teams should evaluate the indication and perform the RDN procedure.
Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including ran-domised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interven-tions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient's global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require exper-tise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available